Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — Q3 FY2024 Earnings Presentation

18 slides from Jcr Pharmaceuticals's earnings presentation, Jan 31, 2025

  1. Slide 1: FY2024 Third Quarter Consolidated Financial Results Conference Call

    FY2024 Third Quarter Consolidated Financial Results Conference Call January 31, 2025 JCR Pharmaceuticals Co., Ltd. [Securities code]4552, Prime. TSE [Contacts] ir-info@jp.jcrpharm.com

  2. Slide 2: FY2024 Third Quarter Consolidated Financial Results

    FY2024 Third Quarter Consolidated Financial Results Yoh Ito Senior Executive Officer Executive Director, Corporate Strategy Division 1

  3. Slide 3: Agenda

    FY2024 Third Quarter Consolidated Financial Results Conference Call 1 FY2024 Third Quarter Consolidated Financial Results 2 Progress of Developmental Pipelines 3 Revision of FY2024 Consolidated Financial Forecast 2

  4. Slide 4: Overview: Consolidated Financial Results

    Overview: Consolidated Financial Results (Unit：million yen) FY2023 FY2024 Additional Remarks Consolidated Year-on-year Q3 YTD Q3 YTD • Cost to sales ratio excluding contractual payment Difference Ratio remained favorable Net Sales 33,718 25,880 (7,837) (23.2%) • Depreciation from the API Plant at Ko

  5. Slide 5: Breakdown of Net Sales (Consolidated)

    Breakdown of Net Sales (Consolidated) (Unit: million yen) FY2023 FY2024 Additional Remarks Consolidated Year-on-year Q3 YTD Q3 YTD • Sales of GROWJECT® increased by 1.3% year- Difference Ratio on-year, reflecting steady growth. GROWJECT® 13,995 14,177 +182 +1.3% • Sales of IZCARGO® grew by 12.3% yea

  6. Slide 6: "First dosing in first subject" was achieved in 3 studies in 3 products

    Progress of Developmental Pipelines “First dosing in first subject” was achieved in 3 studies in 3 products BBB-penetrating heparan N-sulfatase (rDNA origin) JR-441 Indication: MPS type IIIA − Japan: Phase I study (JR-441-JP11) BBB-penetrating α-N-acetylglucosaminidase (rDNA origin) JR-446 Indicatio

  7. Slide 7: Overview of Clinical or late Preclinical Pipeline

    Overview of Clinical or late Preclinical Pipeline Status Code Indication Milestones/Comments Preclinical Phase 1 Phase 2 Phase 3 • Q3 FY2025: Enrollment completion JR-141 MPS II (Hunter syndrome) Global Ph3 • ~FY2027: Approval in US, EU, Brazil • Extension study ongoing JR-171 MPS I (Hurler syndrome

  8. Slide 8: Revision of FY2024 Consolidated Financial Forecast

    Revision of FY2024 Consolidated Financial Forecast Profit Attributable to Net Sales Operating Profit Ordinary Profit Earnings Per Share (Unit: million yen) (Unit: million yen) (Unit: million yen) Owners of Parent (Unit: yen) (Unit: million yen) Previously announced 41,300 5,400 4,600 3,700 29.65 for

  9. Slide 9: Revision of FY2024 Consolidated Financial Forecast

    Revision of FY2024 Consolidated Financial Forecast (Unit: million yen) Previously Reference: Revised forecasts Difference Ratio announced forecasts FY2023 Results GROWJECT® 18,300 18,300 - - 17,913 IZCARGO® 5,700 5,800 +100 +1.8% 5,171 TEMCELL®HS Inj. 2,800 2,900 +100 +3.6% 3,236 Treatments for rena

  10. Slide 10: Reach Beyond, Together MIC?

    Reach Beyond, Together MIC?

  11. Slide 11: Appendix

    Appendix

  12. Slide 12: GROWJECT Market Share Trends in Japan (Quarterly)

    GROWJECT® Market Share Trends in Japan (Quarterly) ■ Human Growth Hormone Market in Japan GH Market Share in Japan (FY2023 Q1～FY2024 Q3) *On an NHI drug price General basis Practitioner(GP) 60.0% 30.8% Hospital (HP) 48.6% 44.7% 50.0% 45.3% 43.7% 43.9% 41.6% 41.8% 41.2% 40.0% 31.7% Pharmacy(PH) 30.1%

  13. Slide 13: GROWJECT Sales Trends in Japan (Quarterly)

    GROWJECT® Sales Trends in Japan (Quarterly) GH Sales Trends in Japan (FY2023 Q1～FY2024 Q3) *On an NHI drug price basis 8,000 18,000 GH Market in Japan （million yen） Sales amount of each product (million yen) 7,000 16,000 14,000 6,000 GH Market in Japan 12,000 5,000 JCR Growject® Daily Product A Dail

  14. Slide 14: IZCARGO Prescription Status in Japan

    IZCARGO® Prescription Status in Japan 売上高（百万円） Administered cases 投与症例数（例） Cumulative cases 累積症例数（例） (million yen) Sales(million yen) (cases) (cases) (cases) 1,800 95 100 92 92 90 88 85 90 1,600 83 77 74 80 1,400 78 75 75 70 1,200 72 73 69 70 60 64 1,000 62 50 800 40 600 30 400 20 200 10 1,249 1,047

  15. Slide 15: Handling of subsidies for the construction of the Kobe Science Park Center

    Handling of subsidies for the construction of the Kobe Science Park Center • In the third quarter financial statement, approximately 500 million yen of the depreciation at Kobe Science Park Center was recorded as SG&A expenses and approximately 100 million yen was recorded as Non-operating expenses.

  16. Slide 16: Abbreviations (A～G)

    Abbreviations (A～G) AAV Adeno-Associated Virus アデノ随伴ウイルス API Active Pharmaceutical Ingredient 原薬 ASO Antisense oligonucleotides アンチセンス核酸 BBB Blood-Brain Barrier 血液脳関門 CNS Central Nervous System 中枢神経系 CSF Cerebrospinal fluid 脳脊髄液 CTN Clinical Trial Notification 治験計画届 EC European Commission 欧州委員会 EMA

  17. Slide 17: Abbreviations (H～Z)

    Abbreviations (H～Z) HS Heparan Sulfate ヘパラン硫酸 i.v. Intravenous Injection 静脈注射 JBC J-Brain Cargo® - LNP Lipid nanoparticle 脂質ナノ粒子 MPS Mucopolysaccharidosis ムコ多糖症 NPS Named Patient Supply 特定の患者への医薬品提供プログラム ODD Orphan Drug Designation 希少疾病用医薬品指定 Ph I Phase I 臨床第１相試験 Ph II Phase II 臨床第２相試験 Ph III Phase

  18. Slide 18: Disclaimer Regarding Forward-Looking Statement

    Disclaimer Regarding Forward-Looking Statement • This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Company’s financial results and other data. Such forward-looking statements are based on the Company’s assumptions, estimates, outlook, and

JCR Pharmaceuticals — Q3 FY2024 Earnings Presentation on 6ix